Michael Derks

A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder

Federico Bolognani, Marta del Valle Rubido, Lisa Squassante et al. · Science Translational Medicine · 2019 · 120 citations

A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABAA-α5 NAM (basmisanil) on intellectual disability associated with Down syndrome

Celia Goeldner, Priya S. Kishnani, Brian G. Skotko et al. · Journal of Neurodevelopmental Disorders · 2022 · 41 citations · Full text

Basmisanil, a highly selective GABAA-α5 negative allosteric modulator: preclinical pharmacology and demonstration of functional target engagement in man

Joerg F. Hipp, Frédéric Knoflach, Robert A. Comley et al. · Scientific Reports · 2021 · 35 citations · Full text

A single-center, open-label, one-sequence study of dalcetrapib coadministered with ketoconazole, and an in vitro study of the S-methyl metabolite of dalcetrapib

Michael Derks, Stephen Fowler, Olaf Kuhlmann · Clinical Therapeutics · 2009 · 24 citations

Medicinal Chemistry, Pharmaceutical Science, Medicine +13

Coadministration of Dalcetrapib With Pravastatin, Rosuvastatin, or Simvastatin: No Clinically Relevant Drug‐Drug Interactions

Michael Derks, Markus Abt, Mary C. Phelan et al. · The Journal of Clinical Pharmacology · 2010 · 23 citations